Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 12Thoracic 4Gastrointestinal 3NET 2CNS 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 2Lung Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 5Ipilimumab 3Everolimus 3lutetium Lu 177 dotatate 2cabozantinib 2atezolizumab 2Temozolomide 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Fluorodeoxyglucose F18 2Etoposide 2Cisplatin 2Capecitabine 2tivozanib 1sintilimab 1repotrectinib 1pralsetinib 1pembrolizumab 1lenvatinib 1copper dotatate CU-64 1belinostat 1avelumab 1Sunitinib 1Somatostatin 1Drug Therapy 1Copper 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 164Cu-DOTATATE 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Cisplatin × NET × Clear all
NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05076786 2021-11-03

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Peking Union Medical College Hospital

Phase 2 Unknown
28 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡